Liu TP - Search Results

1

PF-429242 exhibits anticancer activity in hepatocellular carcinoma cells via FOXO1-dependent autophagic cell death and IGFBP1-dependent anti-survival signaling.

Lin JC, Liu TP, Chen YB, Yang PM. Lin JC, et al. Among authors: liu tp. Am J Cancer Res. 2023 Sep 15;13(9):4125-4144. eCollection 2023. Am J Cancer Res. 2023. PMID: 37818050 Free PMC article.

2

p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.

Yang PM, Hong YH, Hsu KC, Liu TP. Yang PM, et al. Among authors: liu tp. Am J Cancer Res. 2019 Oct 1;9(10):2120-2139. eCollection 2019. Am J Cancer Res. 2019. PMID: 31720078 Free PMC article.

3

Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.

Lin JC, Liu TP, Chen YB, Huang TS, Chen TY, Yang PM. Lin JC, et al. Among authors: liu tp. Toxicol Appl Pharmacol. 2023 Jul 15;471:116568. doi: 10.1016/j.taap.2023.116568. Epub 2023 May 27. Toxicol Appl Pharmacol. 2023. PMID: 37245555

4

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.

Lin JC, Yang PM, Liu TP. Lin JC, et al. Among authors: liu tp. Int J Mol Sci. 2021 May 29;22(11):5848. doi: 10.3390/ijms22115848. Int J Mol Sci. 2021. PMID: 34072570 Free PMC article.

5

Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.

Lin JC, Huang WP, Liu CL, Lee JJ, Liu TP, Ko WC, Huang YC, Hsu ML, Wu CH, Chen YJ. Lin JC, et al. Among authors: liu cl, liu tp. Transplantation. 2013 Mar 27;95(6):791-800. doi: 10.1097/TP.0b013e31827fac48. Transplantation. 2013. PMID: 23354299

6

S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.

Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM. Liu TP, et al. Anticancer Drugs. 2015 Feb;26(2):139-47. doi: 10.1097/CAD.0000000000000166. Anticancer Drugs. 2015. PMID: 25203626 Free PMC article.

7

In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.

Liu TP, Hong YH, Tung KY, Yang PM. Liu TP, et al. Oncoscience. 2016 Jan 29;3(1):9-20. doi: 10.18632/oncoscience.285. eCollection 2016. Oncoscience. 2016. PMID: 26973856 Free PMC article.

8

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells.

Liu TP, Hong YH, Yang PM. Liu TP, et al. Oncotarget. 2017 Sep 16;8(49):86168-86180. doi: 10.18632/oncotarget.21030. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156785 Free PMC article.

9

In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.

Hsieh YY, Liu TP, Yang PM. Hsieh YY, et al. Among authors: liu tp. Pathol Res Pract. 2019 Jun;215(6):152373. doi: 10.1016/j.prp.2019.03.002. Epub 2019 Mar 4. Pathol Res Pract. 2019. PMID: 30871916

10

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.

Hsieh YY, Liu TP, Chou CJ, Chen HY, Lee KH, Yang PM. Hsieh YY, et al. Among authors: liu tp. Genes (Basel). 2019 Sep 28;10(10):766. doi: 10.3390/genes10100766. Genes (Basel). 2019. PMID: 31569425 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters